Crosstalk between EphA2 and BRaf/CRaf is a Key Determinant of Response to Dasatinib

PURPOSE: EphA2 is an attractive therapeutic target due to its diverse roles in cancer growth and progression. Dasatinib is a multi-kinase inhibitor that targets EphA2 and other kinases. However, reliable predictive markers and a better understanding of the mechanisms of response to this agent are ne...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Huang, Jie, Hu, Wei, Bottsford-Miller, Justin, Liu, Tao, Han, Hee Dong, Zand, Behrouz, Pradeep, Sunila, Roh, Ju-Won, Thanapprapasr, Duangmani, Dalton, Heather J., Pecot, Chad V., Rupaimoole, Rajesh, Lu, Chunhua, Fellman, Bryan, Urbauer, Diana, Kang, Yu, Jennings, Nicholas B., Huang, Li, Deavers, Michael T., Broaddus, Russell, Coleman, Robert L., Sood, Anil K.
Format: Artigo
Langue:Inglês
Publié: 2014
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3975695/
https://ncbi.nlm.nih.gov/pubmed/24486585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-2141
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires